Show simple item record

dc.contributor.authorGreystoke, Alastair
dc.contributor.authorO'Connor, James P B
dc.contributor.authorLinton, Kim M
dc.contributor.authorTaylor, M Ben
dc.contributor.authorCummings, Jeffrey
dc.contributor.authorWard, Timothy H
dc.contributor.authorMaders, Fran
dc.contributor.authorHughes, Anthony
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorRadford, John A
dc.contributor.authorDive, Caroline
dc.date.accessioned2012-01-09T12:56:30Z
dc.date.available2012-01-09T12:56:30Z
dc.date.issued2011-02-15
dc.identifier.citationAssessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. 2011, 104 (4):719-25 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid21245866
dc.identifier.doi10.1038/sj.bjc.6606082
dc.identifier.urihttp://hdl.handle.net/10541/200912
dc.description.abstractTreatment efficacy and toxicity are difficult to predict in lymphoma patients. In this study, the utility of circulating biomarkers in predicting and/or monitoring treatment efficacy/toxicity were investigated.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntibodies, Monoclonal, Murine-Derived
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBiomarkers, Pharmacological
dc.subject.meshBleomycin
dc.subject.meshCyclophosphamide
dc.subject.meshDNA
dc.subject.meshDacarbazine
dc.subject.meshDoxorubicin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKeratin-18
dc.subject.meshLymphoma
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNucleosomes
dc.subject.meshPredictive Value of Tests
dc.subject.meshPrednisone
dc.subject.meshPrognosis
dc.subject.meshTumor Markers, Biological
dc.subject.meshVinblastine
dc.subject.meshVincristine
dc.subject.meshYoung Adult
dc.subject.meshfms-Like Tyrosine Kinase 3
dc.titleAssessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, The Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Withington, Manchester M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren
dc.identifier.pmcidPMC3049589
html.description.abstractTreatment efficacy and toxicity are difficult to predict in lymphoma patients. In this study, the utility of circulating biomarkers in predicting and/or monitoring treatment efficacy/toxicity were investigated.


This item appears in the following Collection(s)

Show simple item record